Novartis India Posts Quarterly Results as Ownership Transition is Announced
Novartis India Limited has released its unaudited financial results for the quarter ended June 30, 2026. The company also confirmed details of a major strategic transaction regarding the ownership structure following an agreement signed in February 2026.The company operates within a single segment: the Pharmaceutical Business, generating revenue exclusively from operations within India. For the quarter ending June 30, 2026, one customer contributed R 532.9 million, which represents over 10% of the total revenue from the sale of traded goods.
Financial Highlights for Q ended June 30, 2026
The financial results reflect various income and expense streams during the reporting period. Key figures related to revenue, expenses, and profitability are detailed below (all figures in millions INR):| Particulars | Revenue from Operations Other Income | Changes in Stock-in Trade | Employee Benefits Expense | Finance Costs | Impairment on Receivables | Deferred Tax Expense |
|---|---|---|---|---|---|---|
| Q ended June 30, 2026 | 183.4 | 760.5 | (203.8) | 4.2 | 4.2 | 84.8 |
| 3 Months Ended June 30, 2026 | 1,000.4 | 683.4 | 43.5 | 0.7 | 4.2 | 134.7 |
| Q ended March 30, 2026 | - | 473.9 | 52.9 | 1.0 | 5.3 | 372.2 |
The company recorded a profit before tax of 322.1 million for the quarter ended June 30, 2026. The total comprehensive income for that period stood at 123.4 million.
Financial Indebtedness Status
Novartis India Limited reported no exposure regarding financial indebtedness and outstanding debt securities in its integrated filing. The company confirmed:- Total financial indebtedness of the listed entity, including short-term and long-term debt, was NIL.
- The total amount outstanding for loans or revolving facilities from banks/financial institutions was NIL, with zero default reported.
Strategic Share Acquisition Details
A significant transaction impacting the ownership structure of Novartis India Limited was established on February 19, 2026. This involved an Agreement for the sale and purchase of shares between Novartis AG (the seller) and a group of investors known as the Acquirers.The Acquirers include WaveRise Investments Limited (Acquirer 1), ChrysCapital Fund X (Acquirer 2), and Two Infinity Partners (Acquirer 3). Under this agreement, Novartis AG agreed to sell 1,74,50,680 fully paid-up equity shares of the company. This transaction represents 70.68% of the total equity share capital.
The completion of this acquisition means that the Acquirers will acquire control over the Company and will be classified as the 'promoter' in accordance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The sale was executed following a public announcement for an open offer made by the Acquirer on February 20, 2026, which concluded on June 24, 2026.
NOVARTIND Stock Price Movement
Shares of Novartis India Limited are slipping by 2.49% in live trading as of 1:14 PM, currently valued at ₹1657.50 amidst market activity. The stock continues to trade with strong interest, having previously achieved a remarkable 52-week high of ₹1780 while accumulating 111,867 shares traded today.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.